Retatrutide-Peptide.biz
Cart (0)
98%+ purity, third-party verifiedShips from the USA in 1–2 business daysFree shipping over $200Research use only

Author

Nir Barzilai, MD

He is a Professor of both Medicine and Genetics at Albert Einstein College of Medicine, and there he is also the founding director of the Institute for Aging Research.

Nir Barzilai, MD

Author

He is a Professor of Medicine and Genetics at Albert Einstein College of Medicine and the founding director of the Institute for Aging Research. He devised the TAME metformin trial.

Education and training

StageInstitution
MDReceived his degree from Technion, Israel Institute of Technology in 1985.
ResidencyYale University
Fellowship, MetabolismYale University
Finished a fellowship in Endocrinology and Molecular Medicine.Cornell

Current positions

  • Acts as Professor in the Department of Medicine (Endocrinology) and the Department of Genetics at Albert Einstein College of Medicine.
  • Occupies the Ingeborg and Ira Leon Rennert Chair in Aging Research.
  • Acts as Founding Director of the Institute for Aging Research, also called the Institute for Geroscience.
  • Leads the Nathan Shock Center of Excellence in the Basic Biology of Aging.
  • Leads the Paul F. Glenn Center for the Biology of Human Aging Research.
  • Director, Longevity Genes Project
  • Was chosen as President of the Global Academy for Health & Lifespan Research.

Research areas

His research covers geroscience, the genetics of exceptional longevity, metformin as an anti-aging intervention, nutritional and genetic influences on lifespan, the GH/IGF-1 axis, and metabolism in mammalian aging.

Key discoveries

The Longevity Genes Project includes more than 600 centenarian families and has identified gene variants (CETP, APOC3, ADIPOQ, TSHR, IGF1R) associated with exceptional longevity and protection against cardiovascular disease, cancer, type 2 diabetes, and dementia.

TAME trial

He conceived and designed the TAME (Targeting Aging with Metformin) multicenter trial, which examines whether metformin can delay the onset of multiple age-related conditions at once. The trial's strategic aim is to persuade the FDA to regard aging itself as a treatable condition.

Book

Writer of 'Age Later: Health Span, Life Span, and the New Science of Longevity'. (2020, St. Martin's Press)

Awards

His honors include the Irving S. Wright Award of Distinction in Aging Research (2010), the IPSEN Longevity Award, the NIA Nathan Shock Award, the Beeson Award, the Paul Glenn Foundation Award, and the Senior Ellison Foundation Award. He is a Fellow of the Association of American Physicians and the New York Academy of Medicine.